Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma
Condition(s):NK/T Cell LymphomaLast Updated:November 5, 2020Withdrawn
Hide Studies Not Open or Pending
Condition(s):NK/T Cell LymphomaLast Updated:November 5, 2020Withdrawn
Condition(s):Nasopharyngeal Carcinoma; Leucogen; Chemotherapy; MyelosuppressionLast Updated:March 22, 2023Not yet recruiting
Condition(s):Hematologic MalignancyLast Updated:June 26, 2018Withdrawn
Condition(s):Extranodal NK-T-Cell LymphomaLast Updated:October 22, 2020Unknown status
Condition(s):Acute Lymphoblastic Leukemia; Lymphoblastic LeukemiaLast Updated:November 18, 2023Completed
Condition(s):Hematologic MalignanciesLast Updated:May 7, 2015Completed
Condition(s):Acute Myeloid LeukemiaLast Updated:March 12, 2018Completed
Condition(s):Natural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeLast Updated:September 14, 2021Completed
Condition(s):Drug/Agent Toxicity by Tissue/Organ; LeukemiaLast Updated:November 3, 2023Completed
Condition(s):Nasal and Nasal-type NK/T-cell LymphomaLast Updated:July 17, 2015Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.